12/2
05:21 pm
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
04:31 pm
mist
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects [Yahoo! Finance]
Low
Report
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects [Yahoo! Finance]
11/25
01:54 pm
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/23
02:11 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
11/18
06:27 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate [Yahoo! Finance]
11/12
08:21 am
mist
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
Neutral
Report
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
11/12
07:01 am
mist
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Low
Report
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
11/4
04:05 pm
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
08:00 am
mist
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
Medium
Report
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
10/25
12:09 pm
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/9
08:45 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 [Yahoo! Finance]
10/9
08:00 am
mist
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Medium
Report
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
10/7
08:40 am
mist
Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment [Seeking Alpha]
Low
Report
Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment [Seeking Alpha]
9/11
08:08 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $4.00 price target on the stock.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $4.00 price target on the stock.